Please login to the form below
atrial fibrillation
This page shows the latest atrial fibrillation news and features for those working in and with pharma, biotech and healthcare.
BMS builds case for cardiovascular drug mavacamten with new analysis
In both obstructive or non-obstructive HCM patients, physical exertion can cause fatigue or shortness of breath, and has also been associated with increased risks of atrial fibrillation, stroke, heart failure
Latest news
-
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
In both obstructive or non-obstructive HCM patients, physical exertion can cause fatigue or shortness of breath, and has also been associated with increased risks of atrial fibrillation, stroke, heart failure
-
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis
The FDA has approved Micro Labs and Mylan’s generics to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), one of Eliquis’ key indications.
-
Correvio crumbles as FDA panel rejects AFib drug
drug for atrial fibrillation, citing safety concerns. ... The treatment landscape is currently missing a rapid, efficacious and well tolerated option to treat patients with recent onset atrial fibrillation and we believe Brinavess has the potential to
-
Regeneron reveals first data for bispecific antibody in multiple myeloma
Five patients experienced grade 3 or higher treatment-emergent adverse events, including lymphopenia, hypertension, anaemia, atrial fibrillation fatigue, febrile neutropenia, pain in extremity, septic shock and thrombocytopenia.
-
Apple Watch shows promise in heart study, but doctors sceptical
a role in detecting conditions such as atrial fibrillation, a deadly and often undiagnosed disease. ... partnered with pharma giant Johnson and Johnson to assess the impact of wearable technology on earlier detection of atrial fibrillation.
More from news
Approximately 10 fully matching, plus 118 partially matching documents found.
Latest Intelligence
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
When Novel Oral Anticoagulants (NOACs) entered the market some years ago for the prevention of stroke in atrial fibrillation, the potential for market disruption was clear.
-
Digital disruption in market access
Accession is currently working with the NHS in the UK to prevent the devastating impact of stroke caused by atrial fibrillation (AF) through the use of digital technology.
-
Is it possible to change behaviour virtually?
Clinicians' ability to identify the correct patients for different stroke prevention treatments had been identified as a barrier to optimal management of non-valvular atrial fibrillation (NVAF).
-
Deal Watch table for October 2013
XEN-D103 ion channel modulator for atrial fibrillation (phase I). 162.4. Anacor / Valeant.
-
Interview: Allan Hillgrove, Boehringer
American College of Cardiology (ACC) to educate cardiologists in China about stroke prevention in atrial fibrillation (AF) – a condition for which Boehringer markets Pradaxa (dabigatran).
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Daniel Beach moves from Ketchum to Portland Health
Prior to this, Beach held director-level roles at DBHC Consulting, the Atrial Fibrillation Association, and Just:: Health Communications.
-
Merck & Co’s Jürgen Polifka joins Cardiome
Will lead commercialisation in Europe of atrial fibrillation treatment Brinavess. Jürgen Polifka has left his role at Merck and Co to join Canada-based biopharma Cardiome as general manager, sales and ... Polifka was most recently regional marketing
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
Technology is another important enabler - as seen along the North West coast, where they are using portable ECG technology to screen for atrial fibrillation (AF) in an attempt to bring down
-
Cardiovascular disease: The scale of the challenge
As the audit reveals, too many people with high risk conditions such as atrial fibrillation – a type of irregular heartbeat associated with the most serious strokes and heart attacks – are either
-
The Week After
The Week After looks at the risks associated with atrial fibrillation - the teaser looks to capture the attention of cardiology to step in and act.
-
What is changing in cardiovascular disease care?
Improving the detection and management of high-risk conditions, such as high blood pressure, high cholesterol and Atrial Fibrillation (AF) that can cause CVD, as well as many cases of dementia,
-
Artificial Intelligence in healthcare
enough for you, the National Institute for Health and Care Excellence (NICE) has approved the use of ‘AliveCor’, which is a mobile heart monitor that can detect, monitor, and manage atrial ... fibrillation – a potentially fatal irregular heart
More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- The patient voice – the value of patient-reported outcomes in HTA
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- ONS data reveals significant decrease in COVID-19 antibodies
- Researchers create ‘world’s largest’ database for predicting cancer treatment response
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- ONS data reveals significant decrease in COVID-19 antibodies
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
